EA200900970A1 - Лечение нарушений дыхательной цепи с помощью соединений, имеющих активность эритропоэтина или тромбопоэтина - Google Patents
Лечение нарушений дыхательной цепи с помощью соединений, имеющих активность эритропоэтина или тромбопоэтинаInfo
- Publication number
- EA200900970A1 EA200900970A1 EA200900970A EA200900970A EA200900970A1 EA 200900970 A1 EA200900970 A1 EA 200900970A1 EA 200900970 A EA200900970 A EA 200900970A EA 200900970 A EA200900970 A EA 200900970A EA 200900970 A1 EA200900970 A1 EA 200900970A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- erythropoietin
- compounds
- activity
- thrombopoetin
- disturbances
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/196—Thrombopoietin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Раскрыты способы лечения митохондриальных нарушений, связанных с дефектами дыхательной цепи, с применением соединений, имеющих активность эритропоэтина или тромбопоэтина. Обсуждаются индикаторы для оценки эффективности лечения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87994307P | 2007-01-10 | 2007-01-10 | |
PCT/US2008/000353 WO2008086025A2 (en) | 2007-01-10 | 2008-01-09 | Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200900970A1 true EA200900970A1 (ru) | 2009-12-30 |
Family
ID=39609293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200900970A EA200900970A1 (ru) | 2007-01-10 | 2008-01-09 | Лечение нарушений дыхательной цепи с помощью соединений, имеющих активность эритропоэтина или тромбопоэтина |
Country Status (8)
Country | Link |
---|---|
US (1) | US20100056429A1 (ru) |
EP (1) | EP2101808A4 (ru) |
JP (1) | JP2010515736A (ru) |
CN (1) | CN101610782A (ru) |
AU (1) | AU2008205263A1 (ru) |
CA (1) | CA2674368A1 (ru) |
EA (1) | EA200900970A1 (ru) |
WO (1) | WO2008086025A2 (ru) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005032544A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Treatment of mitochondrial diseases |
EP2471530B1 (en) | 2005-06-01 | 2017-01-11 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
CA2635280C (en) | 2006-02-22 | 2017-12-12 | Edison Pharmaceuticals, Inc. | Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
WO2009061744A2 (en) | 2007-11-06 | 2009-05-14 | Edison Pharmaceuticals, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
EA023618B1 (ru) | 2008-01-08 | 2016-06-30 | Эдисон Фармасьютикалз, Инк. | Производные (гет)арил-п-хинона для лечения митохондриальных болезней |
EP2262508B1 (en) | 2008-03-05 | 2018-10-03 | BioElectron Technology Corporation | SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
US20090291092A1 (en) * | 2008-05-22 | 2009-11-26 | Miller Guy M | Treatment of mitochondrial diseases with an erythropoietin mimetic |
US8716486B2 (en) * | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
WO2010030607A1 (en) | 2008-09-10 | 2010-03-18 | Edison Pharmaceuticals, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
US10039722B2 (en) | 2008-10-14 | 2018-08-07 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
SI2963006T1 (sl) | 2008-10-28 | 2019-01-31 | Bioelectron Technology Corporation | Sestavek vsebujoč alfa-tokotrienol kinon in njegove vmesne povezave |
DK2424495T3 (en) | 2009-04-28 | 2018-04-30 | Bioelectron Tech Corp | TREATMENT OF LEVERS HEREDIC OPTICAL NEUROPATHY AND DOMINANT OPTICAL ATROPHY WITH TOCOTRIENOL QUINONES |
CN102647981B (zh) * | 2009-08-26 | 2016-09-28 | 爱迪生制药有限公司 | 预防和治疗脑缺血的方法 |
WO2011051357A1 (en) * | 2009-10-27 | 2011-05-05 | Loeffler Bernd-Michael | Therapeutic gas for the treatment of mitochondrial disorders |
JP2014520894A (ja) | 2011-07-19 | 2014-08-25 | エジソン ファーマシューティカルズ, インコーポレイテッド | 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法 |
US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
WO2015044704A1 (en) * | 2013-09-30 | 2015-04-02 | Sanofi | Use of neuroglobin agonist for preventing or treating mitochondrial rcci and/or rcciii deficiency disease |
ES2472040B1 (es) * | 2014-02-11 | 2015-07-01 | Miguel Giovanni URIOL RIVERA | Uso de paricalcitol en el tratamiento de la anemia inflamatoria |
KR102626895B1 (ko) | 2014-12-16 | 2024-01-18 | 피티씨 테라퓨틱스, 인크. | (r)-2-하이드록시-2-메틸-4-(2,4,5-트리메틸-3,6-디옥소사이클로헥사-1,4-디에닐)부탄아미드의 다형성 및 무정형 형태 |
WO2017106786A1 (en) | 2015-12-16 | 2017-06-22 | Bioelectron Technology Corporation | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
WO2017106803A1 (en) | 2015-12-17 | 2017-06-22 | Bioelectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
EP3441070A4 (en) * | 2016-04-08 | 2019-12-11 | Keio University | MEDICINES FOR PREVENTING OR TREATING LACTATACIDOSIS |
JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | 2−置換アミノ−ナフト[1,2−d]イミダゾール−5−オン化合物またはその製薬学上許容される塩 |
CN113365616A (zh) | 2018-10-17 | 2021-09-07 | Ptc医疗公司 | 用于抑制和治疗α-突触核蛋白病、tau蛋白病及其他疾病的2,3,5-三甲基-6-壬基环己-2,5-二烯-1,4-二酮 |
KR20210120037A (ko) | 2019-01-25 | 2021-10-06 | 잔센파마슈티카엔.브이. | 수포제 및 가성 가스의 독성 영향 경감 방법 |
AU2022306868A1 (en) | 2021-07-08 | 2024-02-22 | Ptc Therapeutics, Inc. | Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773569A (en) * | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
US6790439B1 (en) * | 1995-06-07 | 2004-09-14 | Zymogenetics, Inc. | Thrombopoietin compositions |
US5767078A (en) * | 1995-06-07 | 1998-06-16 | Johnson; Dana L. | Agonist peptide dimers |
TWI240627B (en) * | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
US7309687B1 (en) * | 1999-04-13 | 2007-12-18 | The Kenneth S. Warren Institute, Inc. | Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin |
EA004766B1 (ru) * | 1999-04-13 | 2004-08-26 | Дзе Кеннет С. Уоррен Инститьют, Инк. | Модуляция функции возбуждаемых тканей за счет периферического введения эритропоэтина |
US6531121B2 (en) * | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
NZ513547A (en) * | 2001-08-13 | 2002-09-27 | Antipodean Biotechnology Ltd | Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone) |
US20030153503A1 (en) * | 2001-12-06 | 2003-08-14 | Klaus Stephen J. | Methods of increasing endogenous erythropoietin (EPO) |
US7129267B2 (en) * | 2002-03-11 | 2006-10-31 | Janssen Pharmaceutica N.V. | Methods for SHP1 mediated neuroprotection |
US7300915B2 (en) * | 2002-06-05 | 2007-11-27 | The Regents Of The University Of California | Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain |
MXPA05000202A (es) * | 2002-06-28 | 2005-09-30 | Johnson & Johnson | Cuerpos mimeicos ch1-deletados de epo de mimetica de mamifero. |
US7037902B2 (en) * | 2002-07-03 | 2006-05-02 | Receptron, Inc. | Affinity small molecules for the EPO receptor |
US20040009908A1 (en) * | 2002-07-10 | 2004-01-15 | Stamler Jonathan S. | Methods for treating or preventing ischemic injury |
DE10234192B4 (de) * | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
US20040091961A1 (en) * | 2002-11-08 | 2004-05-13 | Evans Glen A. | Enhanced variants of erythropoietin and methods of use |
US7393662B2 (en) * | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
AT500929B1 (de) * | 2004-11-09 | 2007-03-15 | Medizinische Uni Wien Muw | Pharmazeutische zubereitung die erythropoietin enthält |
US20090291092A1 (en) * | 2008-05-22 | 2009-11-26 | Miller Guy M | Treatment of mitochondrial diseases with an erythropoietin mimetic |
-
2008
- 2008-01-09 EP EP08705552A patent/EP2101808A4/en not_active Withdrawn
- 2008-01-09 AU AU2008205263A patent/AU2008205263A1/en not_active Abandoned
- 2008-01-09 JP JP2009545599A patent/JP2010515736A/ja not_active Withdrawn
- 2008-01-09 CN CNA2008800019706A patent/CN101610782A/zh active Pending
- 2008-01-09 EA EA200900970A patent/EA200900970A1/ru unknown
- 2008-01-09 CA CA002674368A patent/CA2674368A1/en not_active Abandoned
- 2008-01-09 US US12/522,912 patent/US20100056429A1/en not_active Abandoned
- 2008-01-09 WO PCT/US2008/000353 patent/WO2008086025A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
AU2008205263A1 (en) | 2008-07-17 |
WO2008086025A2 (en) | 2008-07-17 |
JP2010515736A (ja) | 2010-05-13 |
WO2008086025A3 (en) | 2008-12-31 |
CA2674368A1 (en) | 2008-07-17 |
CN101610782A (zh) | 2009-12-23 |
EP2101808A4 (en) | 2011-11-30 |
US20100056429A1 (en) | 2010-03-04 |
EP2101808A2 (en) | 2009-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200900970A1 (ru) | Лечение нарушений дыхательной цепи с помощью соединений, имеющих активность эритропоэтина или тромбопоэтина | |
JO2872B1 (en) | New vehicles | |
CY1120246T1 (el) | Ενωσεις αναστολεων μεταλλοενζυμου | |
MY151551A (en) | Oxadiazole- and oxazole-substituted benzimidazole- and indole-derivatives as dgat1 inhibitors | |
MX2009004047A (es) | Compuestos organicos. | |
CL2016001715A1 (es) | Nuevos inhibidores de glutaminasa | |
BR112015023349A2 (pt) | composto, composição farmacêutica, e, método de tratamento de uma doença, condição de saúde ou distúrbio | |
CO6930356A2 (es) | Compuestos inhibidores de metaloenzimas | |
BR112012027308A2 (pt) | compostos inibidores de metaloenzima | |
EA201001331A1 (ru) | ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-kit И PDGFR | |
BR112014030386A2 (pt) | compostos e composições para modular a atividade de egfr | |
UY35361A (es) | COMPUESTOS PERFLUORADOS DE 5,6-DIHIDRO-4H-1,3-OXAZIN-2-AMINA COMO INHIBIDORES DE BETA-SECRETASA y MÉTODOS DE USO | |
EA200970447A1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
ATE540941T1 (de) | 1-ä2-(2,4-dimethylphenylsulfanyl)phenylüpiperaz n als verbindung mit kombinierter serotoninwiederaufnahme-, 5-ht3- und 5-ht1a- aktivität zur behandlung kognitiver störungen | |
GT200600028A (es) | Compuestos y composiciones como inhibidores de proteina kinasa | |
CR20110103A (es) | Heteroarilos sustituidos | |
EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
WO2014035140A3 (en) | Compounds and compositions for modulating histone methyltransferase activity | |
BRPI0808775A2 (pt) | compostos e composições como moduladores de atividade de gpr119 | |
BR112022003505A2 (pt) | Composições e métodos para tratamento de distúrbios associados a dna repetitivo | |
EA201591278A1 (ru) | Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
UY34280A (es) | Nuevos compuestos que tienen actividad inhibidora frente a la daminoacido oxidasa. | |
EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
EA201390704A1 (ru) | Соединения, ингибирующие металлоферменты |